A5089319958- Psoriasis: Treatment and Pathogenesis
- Health Systems, Economic Evaluations, Quality of Life
- Dermatology and Skin Diseases
- Pharmaceutical studies and practices
- Acne and Rosacea Treatments and Effects
- Autoimmune Bullous Skin Diseases
- Autoimmune and Inflammatory Disorders Research
- Therapeutic Uses of Natural Elements
- Immunodeficiency and Autoimmune Disorders
- Skin Protection and Aging
- Inflammatory Bowel Disease
- Dupuytren's Contracture and Treatments
- Dermatologic Treatments and Research
- Spondyloarthritis Studies and Treatments
- Advancements in Transdermal Drug Delivery
- Urticaria and Related Conditions
- melanin and skin pigmentation
AbbVie (United States)
2021-2025
Icahn School of Medicine at Mount Sinai
2020
Vyne Therapeutics (United States)
2020
Psoriasis is a chronic, inflammatory skin disease often requiring long-term therapy.To evaluate the safety and efficacy of risankizumab in patients with psoriasis.LIMMitless an ongoing phase 3, open-label extension study evaluating continuous 150 mg every 12 weeks for adults moderate-to-severe plaque psoriasis following multiple 2/3 base studies. This interim analysis assessed (ie, monitored treatment-emergent adverse events [TEAEs]) through 304 weeks. Efficacy assessments included...
The long-term benefit-risk profiles of licensed and investigational treatments for moderate-to-severe plaque psoriasis have not been fully characterized.Randomized controlled trials (RCTs) were identified through a systematic literature review 2 May 2021. Bayesian network meta-analyses (NMAs) conducted to compare the efficacy (Psoriasis Area Severity Index [PASI] 75/90/100 [at least 75/90/100% reduction in PASI score from baseline] response) safety outcomes (any adverse event [AE], any...
Abstract Background Treatment of psoriasis with risankizumab has demonstrated superior efficacy to other treatments, such as adalimumab, ustekinumab and secukinumab. Objectives This study compared the safety apremilast in adults moderate plaque eligible for systemic therapy. It also evaluated switching vs. continuing patients who did not achieve ≥ 75% improvement Psoriasis Area Severity Index (PASI 75 nonresponders) after 16 weeks treatment apremilast. Methods 52-week, phase IV, multicentre,...
Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who previously had inadequate response/intolerance to ≥ 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR) and/or 1–2 biologic DMARDs (bDMARD-IR). Herein, we report results through 100 weeks of treatment. a global phase 3 trial. Patients were randomized 1:1...
Psoriasis, a chronic, inflammatory skin disease, requires long-term therapy. Risankizumab is humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit.
Risankizumab has demonstrated superior efficacy compared to other psoriasis treatments, including secukinumab, adalimumab, and ustekinumab; switching risankizumab from treatments shown clinical quality of life (QoL) outcomes. We evaluated the safety directly patients with moderate-to-severe plaque a suboptimal response interleukin (IL)-17 inhibitors (secukinumab or ixekizumab) risankizumab. This 52-week, phase 3b study enrolled (≥ 18 years) who had previously been treated recommended dose...
Introduction
 The IMMpulse study (NCT04908475) demonstrated superior efficacy of risankizumab (RZB) compared to apremilast (APR) in systemic-eligible patients with moderate plaque psoriasis (PsO).
 Material and Methods
 This phase 4, multi-center, randomized, open-label, assessor-blinded, active comparator RZB APR adult PsO. In period A, were randomized 1:2 receive (150 mg) or (30 mg twice daily) for 16 weeks. B, all APR-treated re-randomized 1:1 stratified by their ≥ 75%...
Abstract not available.
Abstract not available.